ASO VISUAL ABSTRACT

ASO Visual Abstract: Failure to Thrive Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: Causes and Consequences

Caroline J. Rieser, MD, MS^{1,2} , Jurgis Alvikas, MD¹, Heather Phelos, MPH³, Lauren B. Hall, MSc¹, Amer H. Zureikat, MD¹, Andrew Lee, MD¹, Melanie Ongchin, MD¹, Matthew P. Holtzman, MD¹, James F. Pingpank, MD¹, David L. Bartlett, MD⁴, and M. Haroon A. Choudry, MD¹

¹Division of Surgical Oncology, Koch Regional Perfusion Center, University of Pittsburgh, Pittsburgh, PA; ²UPMC Cancer Pavilion, Pittsburgh, PA; ³Department of Surgery, University of Pittsburgh, Pittsburgh, PA; ⁴AHN Cancer Institute, Allegheny Health Network, Pittsburgh, PA

Failure to thrive (FTT) is common after cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). It is associated with ostomy, venous thromboembolism events, discharge to a skilled nursing facility,

preoperative chemotherapy, older age, and female sex. FTT readmission within 90 days of discharge after CRS/HIPEC is associated with worse survival (hazard ratio 1.58, $p < 0.01$) [<https://doi.org/10.1245/s10434-021-11100-z>].

DISCLOSURES Caroline J. Rieser, Jurgis Alvikas, Heather Phelos, Lauren B. Hall, Amer H. Zureikat, Andrew Lee, Melanie Ongchin, Matthew P. Holtzman, James F. Pingpank, David L. Bartlett, and M. Haroon A. Choudry have no financial relationships to disclose..